RxDoctor Payments Data

Mathea Salas, DO

Family Medicine · Sonora, CANPI 1184781932

Payments from drug & device makers

$1,321in general payments, 2019–2025

Across 57 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$421
  • Novo Nordisk$265
  • Amgen$245
  • Lilly USA, LLC$98
  • Sanofi$77
  • Novartis$35
  • plus $181 from 9 others

What the payments were for

  • Food & beverage$1,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,321 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$209,420
Medicare patients
551
Services billed
2,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$35,340
EliquisApixaban33$30,333
RybelsusSemaglutide28$29,526
FarxigaDapagliflozin Propanediol19$20,319
XareltoRivaroxaban27$18,954
EntrestoSacubitril/Valsartan15$15,304
TrulicityDulaglutide11$12,378
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$6,808
Levothyroxine Sodium322$4,419
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,265
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,890
Pravastatin Sodium279$3,494
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,136
Venlafaxine Hcl ErVenlafaxine Hcl46$2,942
Atorvastatin Calcium303$2,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$11$35,34032 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$421$31,39143 claims
PfizerEliquis$22$30,33333 claims
Novo NordiskRybelsus$265$29,52628 claims
NovartisEntresto$35$15,30415 claims
Lilly USA, LLCTrulicity$98$12,37811 claims
AbbVieSynthroid$14$2,00952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Sonora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →